These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11157025)

  • 21. Pelvic relapse following subtotal lymphoid irradiation in early stage Hodgkin's disease--an analysis of risk, management, and outcome.
    Tate DJ; Hoppe RT
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1239-44. PubMed ID: 7607947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical versus pathologic stage I and II Hodgkin's disease.
    Cox JD; Stoffel TJ
    Oncology; 1980; 37(5):325-8. PubMed ID: 7443165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
    Coleman M; Kaufmann T; Nisce LZ; Leonard JP
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1235-8. PubMed ID: 10725636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care. Australasian Radiation Oncology Lymphoma Group.
    Barton M; Boyages J; Crennan E; Davis S; Fisher RJ; Hook C; Johnson N; Joseph D; Liew KH; Morgan G
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):227-36. PubMed ID: 7836074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation therapy in clinical stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group.
    Gospodarowicz MK; Sutcliffe SB; Bergsagel DE; Chua T
    Eur J Cancer; 1992; 28A(11):1841-6. PubMed ID: 1389522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can pelvic irradiation be omitted in patients with pathologic stages IA and IIA Hodgkin's disease?
    Goodman RL; Piro AJ; Hellman S
    Cancer; 1976 Jun; 37(6):2834-9. PubMed ID: 949703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
    J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are pelvic irradiation and routine staging laparotomy necessary in clinically staged IA and IIA Hodgkin's disease?
    Griffin T; Gerdes A; Parker R; Taylor E; Hafermann M; Taylor W; Tesh D
    Cancer; 1977 Dec; 40(6):2914-6. PubMed ID: 412583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Swedish Lymphoma Study Group.
    Glimelius B; Kälkner M; Enblad G; Gustavsson A; Jakobsson M; Branehög I; Lenner P
    Ann Oncol; 1994 Nov; 5(9):809-16. PubMed ID: 7848883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone.
    Dühmke E; Diehl V; Loeffler M; Mueller RP; Ruehl U; Willich N; Georgii A; Roth S; Matthaei D; Sehlen S; Brosteanu O; Hasenclever D; Wilkowski R; Becker K
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):305-10. PubMed ID: 8892452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era.
    Zapatero A; López MA; Cerezo L; De Vidales CM; MarIn A; Pérez-Torrubia A
    Hematology; 2002 Feb; 7(1):43-50. PubMed ID: 12171776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.
    Bates NP; Williams MV; Bessell EM; Vaughan Hudson G; Vaughan Hudson B
    J Clin Oncol; 1994 Feb; 12(2):288-96. PubMed ID: 7509382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation therapy in the management of bulky mediastinal Hodgkin's disease.
    Behar RA; Hoppe RT
    Cancer; 1990 Jul; 66(1):75-9. PubMed ID: 2354412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
    Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
    J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mantel irradiation for stage I and stage II Hodgkin's disease--results of a 10 year experience.
    Liew KH; Ding JC; Matthews JP; Ironside PJ; Beadle GF; Cooper IA; Madigan JP; Parkin FG
    Aust N Z J Med; 1983 Apr; 13(2):135-40. PubMed ID: 6577832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group.
    Shankar AG; Ashley S; Radford M; Barrett A; Wright D; Pinkerton CR
    J Clin Oncol; 1997 Jul; 15(7):2622-30. PubMed ID: 9215833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.
    Horning SJ; Hoppe RT; Mason J; Brown BW; Hancock SL; Baer D; Rosenberg SA
    J Clin Oncol; 1997 May; 15(5):1736-44. PubMed ID: 9164180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is pelvic irradiation necessary in stage III1A Hodgkin's disease?
    Hartsell WF; Farah R; Murthy A; Golomb H; Weichselbaum R
    Int J Radiat Oncol Biol Phys; 1990 Sep; 19(3):715-9. PubMed ID: 2211220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
    Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH
    J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.